Amrubicin - Celgene Corporation/Sumitomo Dainippon Pharma

Drug Profile

Amrubicin - Celgene Corporation/Sumitomo Dainippon Pharma

Alternative Names: Amrubicin hydrochloride; Calsed; CNF3140; SM-5887

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Celgene Corporation; Icahn School of Medicine at Mount Sinai; SCRI Development Innovations; Stanford University; Sumitomo Dainippon Pharma
  • Class Anthracyclines; Cytostatic antibiotics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Small cell lung cancer
  • Phase I/II Breast cancer; Multiple myeloma
  • Discontinued Bladder cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jun 2015 Amrubicin is still in Preregistration for Small cell lung cancer (First-line therapy) in China
  • 22 Jun 2015 No recent reports on development identified - Phase-II for Small cell lung cancer (First-line therapy, Combination therapy) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top